XML 75 R41.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Revenue Recognition - Collaboration and License Agreement (Details) |  | 12 Months Ended | 49 Months Ended |  |
--- | --- | --- | --- | --- | ---
Nov. 22, 2020 USD ($) obligation program target | Dec. 31, 2024 USD ($) target | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2024 USD ($) target | Nov. 11, 2024 USD ($) | Nov. 30, 2020 USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] |  |  |  |  |  |  |
Deferred revenue, revenue recognized |  | $ 53,438,000 | $ 64,120,000 |  |  |  |
Unsatisfied performance obligation |  | 59,519,000 |  |  | $ 59,519,000 |  |
Drug discovery services revenue from contracts with customers |  | 207,539,000 | 216,666,000 | $ 180,955,000 |  |  |
Drug Discovery Services |  |  |  |  |  |  |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] |  |  |  |  |  |  |
Drug discovery services revenue from contracts with customers |  | $ 25,143,000 | 54,720,000 | 43,427,000 |  |  |
BMS | Oncology, Neurology, and Immunology Product |  |  |  |  |  |  |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] |  |  |  |  |  |  |
Number of specified biological target | target | 5 |  |  |  |  |  |
Number of neurology targets remaining | target |  | 1 |  |  | 1 |  |
Deferred revenue |  | $ 5,900,000 | 7,300,000 |  | $ 5,900,000 |  | $ 55,000,000.0
Variable consideration amount |  | 482,000,000.0 |  |  | 482,000,000.0 |  |
Research, development and regulatory milestones, amount | $ 257,000,000.0 |  |  |  |  |  |
Variable consideration, commercial milestones, amount | $ 225,000,000.0 |  |  |  |  |  |
Deferred revenue, revenue recognized |  |  |  |  | 32,000,000.0 |  |
Number of performance obligations | obligation | 1 |  |  |  |  |  |
Number of programs under agreement | program | 5 |  |  |  |  |  |
Unsatisfied performance obligation | $ 55,000,000.0 |  |  |  |  |  |
Drug discovery services revenue from contracts with customers |  | 10,800,000 | $ 43,200,000 | $ 22,100,000 |  |  |
Allowance for credit loss, current |  | 0 |  |  | 0 |  |
Novartis Pharma AG | Research, Collaboration and License Agreement | Drug Discovery Services |  |  |  |  |  |  |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] |  |  |  |  |  |  |
Deferred revenue |  | 150,000,000.0 |  |  | 150,000,000.0 |  |
Variable consideration amount |  |  |  |  |  | $ 2,272,000,000 |
Research, development and regulatory milestones, amount |  |  |  |  |  | 892,000,000.0 |
Variable consideration, commercial milestones, amount |  |  |  |  |  | $ 1,380,000,000 |
Deferred revenue, revenue recognized |  | 0 |  |  |  |  |
Novartis Pharma AG | Software Agreement | Drug Discovery Services | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-11-12 |  |  |  |  |  |  |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] |  |  |  |  |  |  |
Revenue, remaining performance obligation, expected timing of satisfaction, period |  |  |  |  |  | 3 years |
Novartis Pharma AG | Collaboration and License Agreement | Drug Discovery Services |  |  |  |  |  |  |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] |  |  |  |  |  |  |
Deferred revenue |  | 116,700,000 |  |  | 116,700,000 |  |
Drug discovery services revenue from contracts with customers |  | 600,000 |  |  |  |  |
Allowance for credit loss, current |  | $ 150,000,000.0 |  |  | $ 150,000,000.0 |  |

X
- Definition Collaborative agreement number of programs. + References No definition available. + Details
Name: | sdgr_CollaborativeAgreementNumberOfPrograms
Namespace Prefix: | sdgr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contract With Customer, Number Of Neurology Target Remaining + References No definition available. + Details
Name: | sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining
Namespace Prefix: | sdgr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Contract With Customer, Number Of Specified Biological Targets + References No definition available. + Details
Name: | sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets
Namespace Prefix: | sdgr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Performance Obligations + References No definition available. + Details
Name: | sdgr_NumberOfPerformanceObligations
Namespace Prefix: | sdgr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Revenue, Remaining Performance Obligation, Variable Consideration Amount + References No definition available. + Details
Name: | sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount
Namespace Prefix: | sdgr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue, Remaining Performance Obligation, Variable Consideration, Commercial Milestones, Amount + References No definition available. + Details
Name: | sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount
Namespace Prefix: | sdgr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue, Remaining Performance Obligation, Variable Consideration, Research, Development and Regulatory Milestones, Amount + References No definition available. + Details
Name: | sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount
Namespace Prefix: | sdgr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-4 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | srt_ProductOrServiceAxis=sdgr_DrugDiscoveryServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sdgr_BristolMyersSquibbMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sdgr_OncologyNeurologyAndImmunologyProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sdgr_NovartisPharmaAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sdgr_ResearchCollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sdgr_SoftwareAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-11-12
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sdgr_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |